来曲唑治疗晚期乳腺癌的临床观察  

LETROZOLE IN THE TREATMENT OF ADVANCED BREAST CANCER

作　　者：郝春芳[1] 江泽飞[1] 宋三泰[1] 刘晓晴[1] 王涛[1] 申戈[1] 张志强[1] 秦燕[1] 

机构地区：[1]军事医学科学院307医院乳癌内科,北京100039

出　　处：《肿瘤研究与临床》2004年第2期100-102,共3页Cancer Research and Clinic

摘　　要：目的:观察来曲唑(Letrozole)治疗晚期乳腺癌的疗效及不良反应。方法:63例晚期乳腺癌患者给予来曲唑(进口或国产)2.5 mg口服,每日1次。结果:63例患者中,可评价疗效者62例,可评价不良反应者63例。完全缓解(CR)0例;部分缓解(PR)9例,占14.5 %;稳定(SD)30例,占48.4 %,其中SD≥6个月10例,占16.1 %;临床获益(CR+PR+SD≥6个月)19例,占30.6 %;病情进展(PD)23例,占37.1 %。一线治疗9例,有效率44.4 %,临床获益率66.7 %。二线治疗19例,有效率10.5 %,临床获益率36.8 %。三线及以上治疗34例,有效率8.8 %,临床获益率26.5 %。骨、软组织和内脏转移有效率依次为13.3 %、12.8 %和11.9 %。治疗中1例因变态反应停药,其余无严重不良反应。结论:来曲唑治疗晚期乳腺癌有一定疗效,药物不良反应轻,患者易于耐受。Objective: To evaluate the efficacy and adverse effects of letrozole for postmenopausal patients with advanced breast cancer. Methods: Sixty- three patients with advanced breast cancer received 2.5 mg/d letrozole as a single agent. Results: All patients were evaluable for adverse effects. Among these 62 patients who were evaluable for efficacy,there was no complete response, 9 (14.5 %) partial response, 30(48.4 %) stable disease, 23(37.1 %) progressive disease,and 19(30.6 %) clinical benefit (CR+PR+SD≥6months). The response rate and clinical benefit was 44.4 %and 66.7 % in first- line treatment, 10.5 % and 36.8 % in second- line treatment, 8.8 % and 26.5 % in more than second- line treatment. The response rate of bone,soft tissue and visceral metastasis was13.3 %,12.8 % and 11.9 %, respectively.One patient stop treatment due to allergic reaction. Conclusion: Letrozole is a well tolerated agent with reasonable efficacy but low toxicity for postmenopausal patients with advanced breast cancer.

关 键 词：晚期乳腺癌 内分泌治疗 来曲唑 

分 类 号：R737.9[医药卫生—肿瘤] R730.54[医药卫生—临床医学]